Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)

Journal of Clinical Oncology

Volumn 21, Issue 18, 2003, Pages 3479-3482

  Culine, Stéphane ^a   Lortholary, Alain ^a   Voigt, Jean Jacques ^a   Bugat, Roland ^a   Théodore, Christine ^a   Priou, Frank ^a   Kaminsky, Marie Christine ^a   Lesimple, Thierry ^a   Pivot, Xavier ^a   Coudert, Bruno ^a   Douillard, Jean Yves ^a   Merrouche, Yacine ^a   Allouache, Jelila ^a   Goupil, Alain ^a   Négrier, Sylvie ^a   Viala, Juliette ^a   Petrow, Peter ^a   Bouzy, Jeannine ^a   Laplanche, Agnès ^a   Fizazi, Karim ^a  

^a CENTRE EUGÈNE MARQUIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOXICITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY;

EID: 0142089723     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.104     Document Type: Article

References (11)

1. Hainsworth JD, Greco FA: Treatment of patients with cancer of an unknown primary site. N Engl J Med 329:257-263, 1993
2. Sporn JR, Greenberg BR: Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol 20:261-267, 1993
3. Miller AB, Hoogstraten B, Staquet B, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
4. Simon R: Optimal two-stage designs for phase II clinical trials in oncology. Control Clin Trials 10:1-10, 1989
5. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
6. Rothman KJ: Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 31:557-560, 1978
7. Culine S, Kramar A, Saghatchian M, et al: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679-4683, 2002
8. Greco FA, Burris HA, Erland JB, et al: Carcinoma of unknown primary site: Long term follow-up after treatment with paclitaxel, carboplatin and etoposide. Cancer 89:2655-2660, 2000
9. Briasoulis E, Kalofonos H, Bafaloukos D, et al: Carboplatin plus paclitaxel in unknown primary carcinoma: A phase H Hellenic Cooperative Oncology Group study. J Clin Oncol 18:3101-3107, 2000
10. Greco FA, Burris HA, Litchy S, et al: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 20:1651-1656, 2002
11. Hainsworth JD, Lennington WJ, Greco FA: Overexpression of Her-2 in patients with poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18:632-635, 2000